{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to BEORO Therapeutics, GmbH. (\"Beoro\") located in Seefeld, Germany.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/06/07/2018-12179.html","cfr_references":[],"citation":"83 FR 26487","comment_url":null,"comments_close_on":"2018-06-22","correction_of":null,"corrections":[],"dates":"Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before June 22, 2018 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-12179","effective_on":null,"end_page":26488,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/06/07/2018-12179.xml","html_url":"https://www.federalregister.gov/documents/2018/06/07/2018-12179/prospective-grant-of-an-exclusive-patent-license-the-development-of-an-anti-bcma-immunotoxin-for-the","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-12179?publication_date=2018-06-07","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-06-07/2018-12179/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":465,"last_updated":"2026-06-25 08:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-06-07/pdf/2018-12179.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-12179.pdf?1528289119","publication_date":"2018-06-07","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/06/07/2018-12179.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T08:04:30Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":26487,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: The Development of an Anti-BCMA Immunotoxin for the Treatment of Human Cancer","toc_doc":"Development of Anti-BCMA Immunotoxin for Treatment of Human Cancer","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":83}